Passage BIO, Inc. 8-K

What Happened
Passage Bio, Inc. announced in a Form 8-K (filed March 10, 2026) that on March 4, 2026 it entered into a lease termination agreement with Hopewell Campus Owner LLC to end the Hopewell Lease (originally dated December 15, 2020). The company agreed to pay a termination fee of approximately $4.8 million and to cover accrued rent through February 14, 2026. The Hopewell Lease covered about 62,000 square feet of laboratory space and had a 15‑year term beginning March 2021. Passage Bio ceased operations at the Hopewell facilities after its January 2025 restructuring.

Key Details

• Termination agreement executed March 4, 2026; disclosed on Form 8-K filed March 10, 2026.
• Approximate termination fee: $4.8 million, plus accrued rent through February 14, 2026.
• Leased space: ~62,000 sq ft laboratory; original lease dated Dec 15, 2020 with a 15‑year term from March 2021.
• Company states cash and cash equivalents are expected to fund operations through Q1 2027, subject to assumptions that may change.

Why It Matters
This is a material agreement termination that creates an immediate, one‑time cash outflow (~$4.8M plus accrued rent) but relieves Passage Bio of ongoing lease obligations for the Hopewell lab space it stopped using after its January 2025 restructuring. The company’s statement that cash on hand is expected to fund operations into the first quarter of 2027 is a key investor metric (cash runway), but management notes that this estimate is based on assumptions that could prove wrong and the runway could be shorter. Investors should weigh the upfront cost against avoided future obligations and monitor subsequent disclosures about liquidity and operating plans.